Search results
Health Care Roundup: Market Talk
The Wall Street Journal· 6 days agoPublished exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0748 ET – The failure of Pfizer’s proposed gene therapy for Duchenne ...
Pfizer's DMD gene therapy falls short in phase 3 trial
Becker’s Hospital Review· 6 days agoPfizer's gene therapy candidate for Duchenne muscular dystrophy failed to meet its primary endpoint in a phase 3 trial, the company said ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 7 days ago, opens new tab said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 6 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Cranbury Pharmaceuticals Receives FDA Approval for First Generic Version of Emflaza Oral Suspension
New Jersey Business Magazine· 6 days agoCranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 5 days agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
MarionMade!: Running to help others who may not be able to walk
Gannett via AOL· 3 days agoThe family then started My DMD hero in 2019 to help other families. “The goal is to meet Duchenne...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via AOL· 7 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
WATCH: Organization modifies Valley family's home for free to help kids in wheelchairs
ABC 15 Phoenix· 5 days agoA Valley family is navigating day-to-day life a little easier thanks to a local organization’s...
After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more By Investing.com
Investing.com· 7 days agoBroadcom (NASDAQ:AVGO) rose 10% after beating EPS and revenue estimates for the second quarter and...